Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 16/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12984893 | 0.86 | NTRK1 (0.45) | NTRK1 | |
| SCHEMBL4086378 | 0.85 | NTRK1 (0.52) | NTRK1 | |
| SCHEMBL27934747 | 0.81 | ADK (0.35) | NTRK1 | |
| SCHEMBL12984829 | 0.78 | NTRK1 (0.42) | NTRK1 | |
| SCHEMBL2026264 | 0.78 | POLB (0.47) | NTRK1POLB | |
| SCHEMBL1229639 | 0.74 | SRC (0.36) | NTRK1SMN1; SMN2 | |
| SCHEMBL4076364 | 0.74 | KDM4E (0.43) | NTRK1HTTRAB9AALOX15MAPT | |
| SCHEMBL4088500 | 0.74 | PDPK1 (0.46) | NTRK1 | |
| SCHEMBL12984956 | 0.70 | NTRK1 (0.39) | NTRK1 | |
| SCHEMBL4088469 | 0.69 | NTRK1 (0.72) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773836-B1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PROD INC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-7595325-B2 | Substituted pyrrolo[2,3-d]pyrimidine derivatives useful in cancer treatment | PFIZER INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1773836-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | Pfizer Products Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | PFIZER INC | 2006-02-16 | — | — | US | disclosed |
| WO-2005116035-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | TP53, DPYD, CCNT1 | NTRK1 3916/4885HTT 3768/4885RAB9A 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.